Rexahn Pharmaceuticals, Inc. (RNN) Stock Rating Upgraded by Zacks Investment Research

Zacks Investment Research upgraded shares of Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) from a hold rating to a buy rating in a research note published on Wednesday, October 4th. Zacks Investment Research currently has $2.75 price objective on the stock.

According to Zacks, “REXAHN PHARMACTICALS is a biopharmaceutical company leveraging its proprietary technology platform to discover, develop and commercialize innovative treatments for cancer, central nervous system disorders, sexual dysfunction and other unmet medical needs. Rexahn’s compounds are designed to uniquely treat various disease states while significantly minimizing side effects in order to allow patients to regain quality of life through therapy. “

A number of other research firms have also recently commented on RNN. Rodman & Renshaw reissued a buy rating and issued a $19.50 price target on shares of Rexahn Pharmaceuticals in a research note on Friday, June 9th. HC Wainwright set a $20.00 price target on shares of Rexahn Pharmaceuticals and gave the stock a buy rating in a research note on Monday, September 11th. Finally, Ifs Securities reissued an outperform rating on shares of Rexahn Pharmaceuticals in a research note on Monday, August 7th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Rexahn Pharmaceuticals presently has an average rating of Buy and an average price target of $13.85.

Shares of Rexahn Pharmaceuticals (NYSEMKT RNN) opened at 2.04 on Wednesday. Rexahn Pharmaceuticals has a 12 month low of $0.13 and a 12 month high of $4.74. The firm’s market capitalization is $58.06 million. The stock has a 50 day moving average price of $2.49 and a 200 day moving average price of $2.33.

COPYRIGHT VIOLATION WARNING: “Rexahn Pharmaceuticals, Inc. (RNN) Stock Rating Upgraded by Zacks Investment Research” was first posted by BBNS and is the sole property of of BBNS. If you are viewing this report on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this report can be viewed at https://baseballnewssource.com/markets/rexahn-pharmaceuticals-inc-rnn-upgraded-at-zacks-investment-research/1697406.html.

A number of hedge funds and other institutional investors have recently modified their holdings of RNN. Sabby Management LLC purchased a new stake in shares of Rexahn Pharmaceuticals in the 2nd quarter worth about $706,000. Susquehanna International Group LLP purchased a new stake in Rexahn Pharmaceuticals during the 2nd quarter valued at about $2,905,000. Finally, Renaissance Technologies LLC grew its position in Rexahn Pharmaceuticals by 17.6% during the 1st quarter. Renaissance Technologies LLC now owns 5,758,391 shares of the company’s stock valued at $2,937,000 after purchasing an additional 862,000 shares during the last quarter.

About Rexahn Pharmaceuticals

Rexahn Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company’s clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance.

Get a free copy of the Zacks research report on Rexahn Pharmaceuticals (RNN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Rexahn Pharmaceuticals (NYSEMKT:RNN)

Receive News & Ratings for Rexahn Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Justin Turner Joining Postseason Legends
Justin Turner Joining Postseason Legends
PED Use Cost Alex Rodriguez Millions and His Reputation
PED Use Cost Alex Rodriguez Millions and His Reputation
Yankees to Send Masahiro Tanaka Against Astros in Game 1
Yankees to Send Masahiro Tanaka Against Astros in Game 1
Red Sox Waste Little Time in Firing John Farrell
Red Sox Waste Little Time in Firing John Farrell
Washington Nationals Sans Strasburg for Game 4 at Wrigley
Washington Nationals Sans Strasburg for Game 4 at Wrigley
Red Sox Beat Houston Sunday to Avoid Elimination
Red Sox Beat Houston Sunday to Avoid Elimination


Leave a Reply

 
© 2006-2017 BBNS.